OUR MISSION
Priovant Therapeutics is a clinical-stage biotechnology company focused on delivering novel therapies for autoimmune diseases with the greatest morbidity and mortality. We are developing oral brepocitinib, a potential first-in-class dual inhibitor of TYK2 and JAK1, across multiple severe autoimmune indications, unlocking new treatment options for patients who are underserved by existing therapies.
OUR TEAM
Matt Ackermann
Senior Director & Head, Global Medical Affairs
Ade Adeboye
Director, Clinical Development
Shauna Anderson
Associate Director, Quality
Rory Bales
Senior Manager, Regulatory Affairs
Kelly Barghausen
Director, Regulatory Affairs
Eric Bashkoff
Senior Software Engineer
Courtney Cupples
Chief Commercial Officer
Mike Donoviel
Field Medical Director
Lisa Dyer
Senior Manager, Clinical Operations
Derek Gonzalez
Clinical Research Associate
Sasha Goriounova
Early Development Fellow
Heather Greene
Associate Director, Statistical Programming
Austin Gromatzky
SVP, Strategy and Business Development
Ruth Hager
Director, Pharmacovigilance
Dan Hazen
Controller
Daniel Herz-Roiphe
Chief Operating Officer
Whitney Holmes
Executive Assistant to the CEO & Team Coordinator
Megan Huey
Head of People
Noriko Iikuni
VP, Clinical Development
Nasif Islam
Director, Strategy and Business Development
Rachael Jankowich
Associate Director, Clinical Operations
Brendan Johnson
SVP, Early Development
Scott Jones
Director, Clinical Operations
Brian Junio
Senior Clinical Research Associate
George Kokkines
General Counsel
Leigh La Barbera
Office Manager & Executive Assistant
Debbie Lee
Associate Director, Accounting
Rob Livingston
VP, CMC
Ryan Mann
Associate, Clinical Operations
Tyler Massaro
Principal Biostatistician
Lisa McConnachie
Associate Director, Nonclinical Development
Scott Mitchell
Senior Director, Analytical Development
Paul Mudd
Chief Development Officer
Karen Onwu
Senior Clinical Research Associate
Sergey Pavlenko
Director, Clinical Operations
Sabrina Pogrebivsky
Manager, Clinical Operations
Lindsey Rios
SVP, Program Management & Clinical Operations
Chiara Salvati
Rotational Analyst
Denise Shortino
VP, Biometrics
Taryn Smith
Patient Evaluation Manager
Tracy Smith
Associate Director, Data Management
Bruce Stevens
SVP, Regulatory Affairs & Quality
David Tromblay
Senior Associate, Quality
Qurratul Ann (Annie) Warsi
Senior Director, Clinical Development
Drew Webster
Director, Operations
Flora Wong
Associate Director, Supply Chain
Frank Zhang
Senior Director, Drug Product Development & Manufacturing
Ben Zimmer
Chief Executive Officer
Ben Zimmer
Chief Executive Officer
Paul Mudd
Chief Development Officer
Courtney Cupples
Chief Commercial Officer
Daniel Herz-Roiphe
Chief Operating Officer
Austin Gromatzky
SVP, Strategy and Business Development
Frank Torti
Executive Chairman
Barbara Dalton
Director
Eric Venker
Director
Ben Zimmer
Chief Executive Officer
Ben Zimmer is CEO of Priovant Therapeutics. He joined Priovant from Roivant, where he was a member of the founding team in early 2015 and held multiple leadership roles across the organization, including as President, Roivant Health, Chief Operating Officer, and Head of Public Affairs. As President, Roivant Health, Ben led the launch and oversight of Roivant's Chinese biopharmaceutical subsidiaries, healthcare technology companies (including Datavant), and computationally powered drug discovery platform (including VantAI and Silicon Therapeutics, now Roivant Discovery). Earlier in his career, Ben was a consultant at McKinsey & Co and co-founded and led a public policy non-profit. He holds a BA magna cum laude from Harvard College and a JD from Yale Law School.
Whitney Holmes
Executive Assistant to the CEO & Team Coordinator
Whitney Holmes is Executive Assistant to the CEO & Team Coordinator at Priovant Therapeutics. She joined Priovant from Roivant Sciences, where she served as Team Coordinator for Roivant Health. Whitney began her career working in asset and executive management, including spending 16 years in roles at Credit Suisse, Golub Capital, and Crown Sterling. Whitney earned a BA in Sociology at Wake Forest University and a Grand Diplome at Le Cordon Bleu Paris.
Paul Mudd
Chief Development Officer
Paul Mudd, PharmD, MBA, RPH is Chief Development Officer at Priovant Therapeutics. Before joining Priovant, Dr. Mudd spent over 6 years in the Roivant family, helping to launch and lead companies including Myovant and Urovant. Most recently, he served as the SVP, Clinical Development and Health Outcomes at Urovant, leading GEMTESA® (vibegron) development from in-license to approval. Dr. Mudd has over 20 years of experience as a drug developer, including over 16 years at GSK as a Senior Director of Clinical Pharmacology and R&D Project Leader. Dr. Mudd received his BS in Chemistry and PharmD from the State University of New York at Buffalo and completed a post-doctoral fellowship in Clinical PK/PD and an MBA at the University of North Carolina at Chapel Hill.
Matt Ackermann
Senior Director & Head, Global Medical Affairs
Matt Ackermann is Senior Director & Head, Global Medical Affairs at Priovant Therapeutics. Matt brings more than 20 years of experience in Medical Affairs, including field and leadership positions. He has supported the development and launch of both small molecules and biologics for rare and autoimmune diseases, most recently at ChemoCentryx, where he served as Senior Medical Science Liaison. Matt holds a BA in Biochemistry from University of Kansas and a PhD in Biochemistry/Virology from the University of Kansas Medical Center.
Ade Adeboye
Director, Clinical Development
Ade Adeboye is Director, Clinical Development at Priovant Therapeutics. Ade is a trained physician with multiple years of clinical development and medical monitoring experience across several therapeutic areas including immunology, gastroenterology, rheumatology, oncology, and infectious disease. Prior to joining Priovant, Ade spent three years at Cristcot, where he managed Phase 2 and Phase 3 trials for a number of autoimmune indications. Previously, he served as a Clinical Research Physician at Parexel, where he supervised medical monitoring and pharmacovigilance for a variety of clinical trials. Ade holds an MBBS from the University of Lagos, Nigeria.
Shauna Anderson
Associate Director, Quality
Shauna Anderson is Associate Director, Quality at Priovant. She joined Priovant from Precision BioSciences, where she was a QA Associate on the External QA team. Shauna started her career in the laboratory and has since held various QA roles at several clinical-stage biotechnology companies. She holds a MS and BS in Chemistry and is an ASQ-certified CQA.
Kelly Barghausen
Director, Regulatory Affairs
Kelly Barghausen, PhD is Director, Regulatory Affairs at Priovant Therapeutics. She joined Priovant from Urovant, where she was Associate Director of Regulatory Affairs, making significant contributions to the EMPOWUR study and the submission and FDA approval of the original NDA for GEMTESA® (vibegron). Kelly started her career in Regulatory Affairs at Duke University and has a background in molecular genetics, oncology, and pre-clinical disease modeling. She holds a PhD in Biomedical Sciences from Florida State University College of Medicine as well as a Regulatory Affairs Certification (RAC US).
Rory Bales
Senior Manager, Regulatory Affairs
Rory Bales is Senior Manager, Regulatory Affairs at Priovant Therapeutics. Rory brings more than six years of experience working with both sponsor organizations and CROs. He began his career with Cempra Pharmaceuticals in the Regulatory group, went on to join Triangle Regulatory Publishing and, most recently, spent two years at Impact Pharmaceutical Services where he served as a Senior Submission Specialist. Rory holds a BA from East Carolina University and a MS of Regulatory Affairs from George Washington University, and earned a Regulatory Affairs Certification (RAC) in 2020.
Courtney Cupples
Chief Commercial Officer
Courtney Cupples is Chief Commercial Officer at Priovant Therapeutics. Courtney joined Priovant from Biohaven Pharmaceuticals, where she spent five years leading commercial strategy and launch-planning for the company’s rare disease portfolio, as well as business development projects and global partnering efforts. Prior to Biohaven, Courtney worked at Alexion Pharmaceuticals for nine years, where she led the $1 billion Global Franchise for Soliris® (eculizumab) for atypical Hemolytic Uremic Syndrome (aHUS) and the Global Metabolic Franchise for Strensiq® (asfotase alfa) and Kanuma® (sebelipase alfa) for rare metabolic diseases. Earlier in her career, Courtney spent 11 years at Genzyme in various commercial roles that included a four-year assignment in Chile and three years leading a marketing team in Mexico. Courtney received her BA in Sociology/Anthropology from Swarthmore College.
Mike Donoviel
Field Medical Director
Mike Donoviel is Field Medical Director at Priovant Therapeutics. Mike brings more than 25 years of experience in medical affairs, drug discovery and development, and academic research. He left academia to join Lexicon Pharmaceuticals, where his team brought the company’s first immunomodulatory asset from target validation through Phase 2B clinical trials in RA. He has also held senior field-based medical affairs roles with Ikaria, Therakos, Mallinckrodt, and Arena supporting immunomodulatory therapies across a wide range of therapeutic areas, including autoimmunity, immuno-oncology, rheumatology, dermatology, and gastroenterology. Mike holds a BS in Biochemistry and Cellular Biology from the University of California, San Diego and a PhD in Molecular Genetics from the University of Washington, and completed a postdoctoral fellowship in Medical Genetics at the University of Toronto.
Lisa Dyer
Senior Manager, Clinical Operations
Lisa Dyer is Senior Manager, Clinical Operations at Priovant Therapeutics. Lisa brings more than 18 years of experience in ophthalmology and clinical research. She has worked closely with sites, sponsors, and CROs in Phase II - IV clinical drug and device studies across multiple therapeutic areas, including ophthalmology, infectious disease, autoimmune disease, oncology, and vaccines. Lisa holds a BS in Health Science from ECPI University and a MS in Clinical Operations and Healthcare Management from George Washington University.
Derek Gonzalez
Clinical Research Associate
Derek Gonzalez is a Clinical Research Associate at Priovant Therapeutics. Before joining Priovant, Derek spent three years as a Clinical Research Coordinator, and then went on to supervise the Clinical Research Coordinator team, in the Department of Surgery at the University of Wisconsin. Derek received his Bachelor of Science in Biology and minored in Chemistry and Earth and Ocean Sciences at Duke University.
Sasha Goriounova
Early Development Fellow
Sasha Goriounova is an Early Development Fellow at Priovant Therapeutics. Prior to joining Priovant, Sasha earned a PhD in Pharmacology from the University of North Carolina, Chapel Hill. Her thesis research involved the development of a novel Orai1 Ca2+ channel inhibitor, ELD607, which reduces inflammation in disease models and aids in more efficient bacterial clearing during infection. Sasha also holds bachelor's degrees in Chemistry and Forensic Science from the University of New Haven.
Heather Greene
Associate Director, Statistical Programming
Heather Greene is Associate Director, Statistical Programming at Priovant Therapeutics. Before joining Priovant, Heather was Senior Principal Statistical Programmer/Associate Director at Urovant, where she led all programming activities related to the GEMTESA development program. Earlier in her career, she worked as a statistician at RTI International and spent four years in statistical programming roles at Synteract supporting clinical studies a variety of therapeutic areas including oncology, ophthalmology, dermatology, and gastroenterology. Heather holds a BS in Mathematics and Statistics from UNC Wilmington and a MPH in Biostatistics from UNC Chapel Hill.
Ruth Hager
Director, Pharmacovigilance
Ruth Hager is Director, Pharmacovigilance at Priovant Therapeutics. Ruth holds a Bachelor of Science degree in Nursing from Northeastern University and worked in critical care and research before starting her career in the pharmaceutical industry. She has previously worked for pharma companies within multiple therapeutic areas, as well as a large CRO. Her expertise includes management of all aspects of pharmacovigilance from clinical drug development (phase I through IV) to management of marketed compounds, aggregate report management, safety surveillance, safety database governance, regulatory compliance, vendor management, and audits.
Noriko Iikuni
VP, Clinical Development
Noriko Iikuni, MD, PhD, FACP is VP, Clinical Development at Priovant Therapeutics. Noriko is a board-certified rheumatologist and internist who brings extensive experience in clinical development, medical affairs, and pharmacovigilance across therapeutic areas including rheumatology, immunology, dermatology, gastroenterology, cardiovascular, diabetes, and men’s/women’s health. Prior to joining Priovant, Noriko helped lead late-stage dermatomyositis clinical trials at Alexion and JAK inhibitor development at Pfizer and Eli Lilly. Noriko holds a BS in Biology from Lafayette College, an MD from Kanazawa Medical University (Japan), and a PhD in Rheumatology at Tokyo Women’s Medical University. Noriko also completed a postdoctoral fellowship at the University of California, Los Angeles.
Rachael Jankowich
Associate Director, Clinical Operations
Rachael Jankowich, RN, MSN is Associate Director, Clinical Operations at Priovant Therapeutics. She joined Priovant from Urovant, where she provided cross-functional oversight to the GEMTESA® (vibegron) development program through NDA approval. Prior to Urovant, she worked for over 20 years in clinical research in a broad range of therapeutic areas including Urology, Cardiovascular, CNS, Hematology/Oncology, Infectious Diseases, and Rare Diseases. She earned a master's degree in Clinical Research Management from the University of California, San Francisco.
Brendan Johnson
SVP, Early Development
Brendan Johnson, PhD is SVP, Early Development for Priovant Therapeutics. Prior to joining Priovant, Brendan held clinical pharmacology leadership positions at Roivant Sciences and Sumitovant Biopharma. Earlier in his career, he spent 10 years at GSK in the Clinical Pharmacology Modeling and Simulation Department. Brendan completed his pharmacy training and PhD at Monash University in Melbourne, followed by a clinical PK/PD fellowship with UNC-Chapel Hill and GSK, leading to his long-term role with the company.
Scott Jones
Director, Clinical Operations
Scott Jones is Director, Clinical Operations at Priovant Therapeutics. Before joining Priovant, Scott worked at Faeth Therapeutics, where he supported the operation of clinical trials related to cancer therapies and nutrition. Earlier in his career, Scott spent nearly a decade in the culinary industry, serving as a chef and Culinary Director at Barbara Lynch Collective, where he led teams at some of Boston's finest restaurants, and as Chief of Staff at Chew, a boutique consultancy. Scott holds a BA in Biochemical Sciences from Harvard University.
Brian Junio
Senior Clinical Research Associate
Brian Junio is Senior Clinical Research Associate at Priovant Therapeutics. Before joining Priovant, he spent three years as a Clinical Research Associate in CRO and sponsor organizations. Brian began his career as a Study Coordinator and Project Manager in an oncology precision medicine laboratory, focusing on bringing targeted therapies to patients with blood cancers. Brian holds a BS in Liberal Arts and Sciences from Portland State University and is a Certified Clinical Research Professional (CCRP).
Leigh La Barbera
Office Manager & Executive Assistant
Leigh La Barbera is Office Manager & Executive Assistant at Priovant Therapeutics. Leigh brings over 12 years of administrative support experience as an Executive Assistant across various industries. Prior to joining Priovant, she served as Executive Assistant to the CEO and CFO at Vault Health. Leigh holds a BA in Communications from the University of Minnesota—Twin Cities.
Rob Livingston
VP, CMC
Rob Livingston is VP, CMC at Priovant Therapeutics. He joined Priovant from Repare Therapeutics, where he led pharmaceutical development and clinical supply operations for multiple oncology programs. Rob brings more than 20 years of experience in clinical- and commercial-stage drug development and manufacturing, including leadership roles in drug substance and analytical development at both large pharma and small biotech companies. He received BA degrees in Chemistry and History from Williams College and his PhD in Organic Chemistry from Stanford University.
Ryan Mann
Associate, Clinical Operations
Ryan Mann is Associate, Clinical Operations at Priovant Therapeutics. Before joining Priovant, Ryan spent time as a consultant at Bain & Company and as a product manager at a logistics startup. Ryan earned his BSE in Biomedical Engineering and BA in Computer Science from Duke University.
Tyler Massaro
Principal Biostatistician
Tyler Massaro, PhD, is Principal Biostatistician at Priovant Therapeutics. Before joining Priovant, Tyler held positions both as a CRO and sponsor biostatistician. Most recently, he worked at UCB on the Bimzelx® clinical development program. Tyler received his BA in Mathematics from SUNY College at Geneseo, and his PhD in Mathematics from the University of Tennessee.
Lisa McConnachie
Associate Director, Nonclinical Development
Lisa McConnachie is Associate Director, Nonclinical Development at Priovant Therapeutics. She joins the Priovant team from Impel NeuroPharma, a small commercial stage biotechnology company, where she spent two years leading the company's nonclinical programs for drug-device development, with emphasis on nasal drug delivery. Prior to that role, Lisa spent 17 years with the University of Washington working as a Research Scientist in pharmacokinetics, drug metabolism and toxicology, with an emphasis on translational sciences. Lisa holds a BS in Biology from Purdue University, and a MS in Toxicology and PhD in Pharmaceutics (Drug Metabolism and Pharmacokinetics) from the University of Washington.
Scott Mitchell
Senior Director, Analytical Development
Scott Mitchell is Senior Director, Analytical Development at Priovant Therapeutics. Before joining Priovant, Scott led Analytical and CMC activities at Angion. Prior to that role, he spent 17 years at Gilead Sciences, where he supported drug substance and drug product development from pre-IND through commercialization. Scott holds a BA from Gustavus Adolphus College and a PhD in Pharmacy/Medicinal Chemistry from the University of Utah, and pursued post-doctoral research at the Scripps Institution of Oceanography studying marine natural products.
Karen Onwu
Senior Clinical Research Associate
Karen Onwu is Senior Clinical Research Associate at Priovant Therapeutics. Before joining Priovant, Karen spent ten years as a Clinical Research Associate in CRO and sponsor organizations. In this capacity, she supported clinical trials in oncology, medical device, infectious disease, and endocrinology. Karen holds a Bachelor of Science in Nursing from West Coast University.
Sergey Pavlenko
Director, Clinical Operations
Sergey Pavlenko, MD, is Director, Clinical Operations at Priovant Therapeutics. Sergey brings over 16 years of clinical research experience in Clinical Operations and Project Management. Prior to joining Priovant, Sergey spent more than nine years with Biorasi, a US-based global CRO. As Director of Project Management at Biorasi, he managed multifunctional and multinational teams, primarily focusing on difficult-to-enroll patient populations and rescue studies. Sergey graduated from Novosibirsk State Medical University (Russia) and completed a residency in neurology. He also holds a postgraduate diploma in Clinical Research from the University of Liverpool (UK).
Sabrina Pogrebivsky
Manager, Clinical Operations
Sabrina Pogrebivsky is Manager, Clinical Operations at Priovant Therapeutics. Before joining Priovant, Sabrina spent three years in a field technical role in the Cardiac Rhythm Management division of Boston Scientific. Sabrina earned her B.S.E. in Biomedical Engineering from Duke University.
Lindsey Rios
SVP, Program Management & Clinical Operations
Lindsey Rios is SVP, Program Management & Clinical Operations at Priovant Therapeutics. She brings over 15 years of experience in clinical research. Before joining Priovant, she was Senior Vice President of Project Operations at Biorasi, a global CRO focused on rare disease. As an early employee of Biorasi, Lindsey helped build the delivery arm of the organization and was responsible for leading high-performing global teams in cross-functional clinical programs. Lindsey holds a BS from University of Miami and completed the General Management Program at Harvard Business School.
Chiara Salvati
Rotational Analyst
Chiara Salvati is Rotational Analyst at Priovant Therapeutics. Prior to joining Priovant, Chiara worked on the CMC team at Roivant Sciences, where she supported the development of several clinical-stage assets. She holds a BSE in Chemical & Biological Engineering from Princeton University.
Denise Shortino
VP, Biometrics
Denise Shortino, MS is VP, Biometrics at Priovant Therapeutics. She joined Priovant from Urovant, where she led biostats, programming, and data management for the GEMTESA® (vibegron) development program. Denise has more than 20 years of experiences as a biostatistician in pharmaceutical clinical research and development, including leadership roles at GSK and Parexel. She has successfully supported regulatory submissions for cardiovascular, infectious disease and urology medicines. Denise has an MS in Biostatistics from UNC Chapel Hill and a BS in Statistics from Virginia Polytechnic University.
Tracy Smith
Associate Director, Data Management
Tracy Smith is Associate Director, Data Management at Priovant Therapeutics. Tracy brings more than 20 years of experience in the pharmaceutical industry, both in sponsor organizations and CRO companies. She began her career in clinical information systems and spent several years in SAS programming before moving to data management. Tracy holds a BS in Computer Science from North Carolina Agricultural and Technical State University and will complete her MS in Clinical Research at Campbell University later this year.
Bruce Stevens
SVP, Regulatory Affairs & Quality
Bruce Stevens is SVP, Regulatory Affairs & Quality at Priovant Therapeutics. He joined Priovant from Precision BioSciences, where he was the VP of Quality and Compliance. Bruce has over 25 years of experience in Quality, Validation, Engineering and Manufacturing, including leadership roles at multiple clinical-stage biotech companies, where he developed and implemented phase-appropriate Quality Management Systems, and 10 years of progressive experience at Biogen. He holds degrees in Biological Engineering and Biochemistry from Purdue University.
Daniel Herz-Roiphe
Chief Operating Officer
Daniel Herz-Roiphe is Chief Operating Officer at Priovant Therapeutics. Before joining Priovant, Daniel held various leadership roles in the Roivant family of companies, most recently as Chief Operating Officer & General Counsel at VantAI. Earlier in his career, he worked at Palantir Technologies, Kirkland & Ellis, and McKinsey & Co., and clerked for Chief Judge Merrick Garland on the D.C. Circuit Court of Appeals and Justice Stephen Breyer on the U.S. Supreme Court. He holds a BA summa cum laude from Harvard College and a JD from Yale Law School.
Eric Bashkoff
Senior Software Engineer
Eric Bashkoff, MD, MS is Senior Software Engineer at Priovant Therapeutics. Prior to joining Priovant, Eric served in several full-stack software engineer roles focused on using agile processes in software design to support drug development and commercialization. Before becoming a software engineer, Eric worked as a general surgeon in a community practice, performing over 7000 surgical procedures. He graduated summa cum laude from Princeton University with a BS in Electrical Engineering and Computer Science and received his medical degree from the Mount Sinai School of Medicine. He also holds an MS in Information Technology/Information Assurance from University of Maryland Global Campus.
Dan Hazen
Controller
Dan Hazen is the Controller at Priovant Therapeutics. He has over 13 years of financial and accounting experience, most recently as the Controller at Esperion Therapeutics. He joined Esperion during its early biotech stage and helped create and implement many of the financial, accounting, and operational processes that supported its transition from R&D to commercialization. Prior to Esperion, Dan worked at PwC in its assurance practice, where he earned his CPA. Dan holds a BBA and MBA from the University of Michigan.
Megan Huey
Head of People
Megan Huey is Head of People at Priovant Therapeutics. Prior to joining Priovant, Megan spent more than a decade in people operations leadership roles in healthcare and emerging technologies. She most recently served as Chief People Officer at PerfectServe, a clinical communications SaaS company, and has previously held similar leadership roles at other growing healthcare technology companies. Earlier in her career, she co-founded a healthcare services company where she led people operations and talent acquisition for clinical staffing programs at Army and Navy medical facilities across the globe. Megan holds a BA from University of Maryland.
George Kokkines
General Counsel
George Kokkines is General Counsel at Priovant Therapeutics. George joined Priovant from Novartis Gene Therapies, where he was Vice President of Legal. George brings more than two decades of life sciences experience as a legal executive, including serving as Deputy General Counsel at Takeda Pharmaceuticals. George began his career as a litigator at Sidley Austin. He received a BA in Economics, with Highest Distinction, from the University of Michigan and his JD magna cum laude from Harvard Law School.
Debbie Lee
Associate Director, Accounting
Debbie Lee is Associate Director, Accounting at Priovant Therapeutics. Debbie has over 20 years of finance and accounting experience, most recently as Finance Manager at Esperion Therapeutics. She joined Esperion more than eight years ago during its early R&D stages and supported the company through commercialization, helping to establish financial operations and leading various system implementations. Prior to Esperion, Debbie worked on the internal accounting team at Plante Moran, one of the nation’s largest CPA and business advisory firms. Debbie holds a BBA from Walsh College.
Taryn Smith
Patient Evaluation Manager
Taryn Smith, PA-C is Patient Evaluation Manager at Priovant Therapeutics. Taryn is an experienced clinician with almost a decade of experience caring for patients in the fields of Immunology, Asthma/allergy, Urogynecology and Psychiatry. Before becoming a physician assistant, she worked for the Oklahoma Medical Research Foundation and served as a Fleming Scholar. Taryn holds a BS in Nutritional Science summa cum laude from Oklahoma State University and a Master's of Health Science from the University of Oklahoma Health Sciences Center.
David Tromblay
Senior Associate, Quality
David Tromblay is Senior Associate, Quality at Priovant Therapeutics. He joins Priovant from Elevar Therapeutics where he was a Senior QA Specialist on the Clinical QA team. David began his career at a global CRO and has performed a variety of Quality Assurance activities such as planning and conducting audits, process improvement, and regulatory inspection support. He holds a BS in Information Technology from the University of Cincinnati and is an SQA-certified RQAP-GCP.
Annie Warsi
Senior Director, Clinical Development
Annie Warsi, MD, MAS is Senior Director, Clinical Development at Priovant Therapeutics. Annie is a pharmaceutical industry physician who brings extensive experience in clinical development, clinical research methods, and regulatory filings, including two approved indications in the US and EU. She joins Priovant from Mirum Pharmaceuticals where she was Medical Director, Clinical Development and led clinical trials of ileal bile acid transport inhibitors (IBATi) in hepatology/immunology and obstetrics indications. Prior to that role, Annie spent three years at Myovant Sciences, where she provided leadership and medical oversight for the company's two phase 3 clinical development programs for relugolix combination therapy. Annie holds an MBBS/MD from Ziauddin Medical College and an MAS in Clinical Research from the University of California, San Francisco.
Drew Webster
Director, Operations
Drew Webster is Director, Operations at Priovant Therapeutics. Prior to joining Priovant, Drew served in a variety of strategy and business development roles at Roivant Sciences. Most recently, she was a Senior Analyst of Corporate Development, where she helped drive growth for the company through strategic M&A transactions. Drew received her BS from Duke University in Biomedical Engineering.
Flora Wong
Associate Director, Supply Chain
Flora Wong is Associate Director, Supply Chain at Priovant Therapeutics. Flora joined Priovant from CymaBay Therapeutics. Earlier in her career, she also worked in Supply Chain at Gilead Sciences and Ardelyx Therapeutics. Flora entered the biopharmaceutical industry after earning her degree in Biology and Economics in UC Santa Cruz and recently completed an MBA in Operations and Supply Chain Management in May 2021.
Frank Zhang
Senior Director, Drug Product Development & Manufacturing
Frank Zhang is Senior Director, Drug Product Development & Manufacturing at Priovant. Frank has over 20 years of experience in pharmaceutical drug product development and commercialization, covering various dosage forms. Frank spent his early career at Merck and Schering-Plough in scientific roles across formulation development and technology transfer. Prior to joining Priovant, he was Director of Pharmaceutical Development at TG Therapeutics, where he led drug product development for new chemical entities with focus on manufacturing process development. Frank holds a BS in Mechanical Engineering from Shanghai Jiao Ton University, and a MS and PhD in Mechanical Engineering from State University of New York at Buffalo.
Austin Gromatzky
SVP, Strategy and Business Development
Austin Gromatzky is SVP, Strategy and Business Development at Priovant Therapeutics, where he is responsible for product strategy, portfolio management, and the company's business development activities. Prior to joining Priovant, Austin served in a variety of business development roles at Roivant Sciences, most recently as Head of Business Development for Roivant's China-focused subsidiaries. Austin began his career as a healthcare investments analyst covering therapeutics and medical devices. He received his BS from MIT in Biology and Management Science (Finance).
Nasif Islam
Director, Strategy and Business Development
Nasif Islam is Director, Strategy and Business Development at Priovant Therapeutics. Prior to joining to Priovant, Nasif was a healthcare investment banker at Credit Suisse, where he advised small- and mid-cap biotech companies on mergers, acquisitions, and financing. Before Credit Suisse, Nasif was a strategy consultant at Trinity Partners, where he worked with a wide range of biotech and pharma companies on corporate strategy, market research, and business development. Nasif holds a PhD in regenerative medicine from The Johns Hopkins University School of Medicine and a BS from Cornell University.
Frank Torti
Executive Chairman
Frank Torti is the Vant Chair at Roivant Sciences. Dr. Torti serves as Chairman of the Board of the companies in the Roivant Pharma family and is responsible for the management of those businesses. He previously served as Vant Investment Chair, where he oversaw a group of companies responsible for the development of thirty-five investigational drugs in eleven therapeutic areas and over fifty clinical trials, including four successful Phase 3 trials.
Dr. Torti joined Roivant in 2018 from New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. At NEA, Dr. Torti managed early and growth-stage investments in numerous healthcare companies that were responsible for the development and commercialization of new drugs and medical devices important to clinical medicine today.
Prior to joining NEA in 2007, Dr. Torti was a researcher at the Duke University Center for Clinical & Genetic Economics. Dr. Torti received his MD from the University of North Carolina School of Medicine and his MBA with distinction from Harvard Business School.
Barbara Dalton
Director
Barbara Dalton is Senior Managing Partner, Pfizer Ventures and Vice President, Worldwide Business Development at Pfizer. She has led Pfizer Ventures since joining Pfizer in 2007. The Pfizer Ventures team has invested in over 110 companies and approximately 20 funds, pursuing products, technologies and services, relevant to all aspects of Pfizer's business. Barbara has overall responsibility for Pfizer Ventures and directly manages investments in all funds and in the portfolio companies AMRA, Artios, Cydan, Imara, Ixchelsis, Levicept, Ravenna, Resilience, Saama, Second Genome, and Simcha. She also chairs the Healthcare Advisory Board of the Partnership Fund for NYC.
Barbara's pharmaceutical career started in the Immunology Division of Smith Kline & French Research Laboratories. She moved to venture investing in 1993 when she joined their venture capital group, S.R. One, Limited. In 2000 Barbara became a General Partner in EuclidSR Partners, the private venture fund that was supported by GSK (then SB) as a sister fund to S.R. One, Limited.
Barbara received her undergraduate degree from Penn State and PhD in Immunology and Microbiology from the Medical College of Pennsylvania (now Drexel University School of Medicine).
Eric Venker
Director
Eric Venker is President and Chief Operating Officer of Roivant Sciences. He first joined Roivant in 2014 and has since served in various roles of increasing responsibility, including Chief of Staff to the CEO. Prior to joining Roivant, Dr. Venker was a physician at New York Presbyterian Hospital, Columbia University Medical Center, where he trained in internal medicine. While there, Eric served as the Chair of the Housestaff Quality Council and led operational initiatives to improve efficiencies across a large hospital system with $5 billion in annual revenue. Earlier in his career, Eric was a Clinical Pharmacist at Yale-New Haven Hospital. He received his PharmD from St. Louis College of Pharmacy and his MD from Yale School of Medicine.